A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of patients with Dose Limiting Toxicities (DLTs)

  Measured over: Up to 21 days

• Incidence and severity of treatment-emergent adverse events (TEAEs)

  Measured over: Through study completion, an average of 12 years

• Incidence and severity of adverse events of special interest (AESIs)

  Measured over: Through study completion, an average of 12 years

• Incidence and severity of serious adverse events (SAEs)

  Measured over: Through study completion, an average of 12 years

• Incidence and severity of grade ≥3 laboratory abnormalities

  Measured over: Through study completion, an average of 12 years

• REGN5093 concentrations in serum over time

  Measured over: Through study completion, an average of 12 years

• Objective response rate (ORR) per RECIST 1.1

  Measured over: Through study completion, an average of 12 years

Changes Tremor has spotted